⚕ GalenOps field
←

SITE012-0100

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2022-06-20

AEs
5
Serious
1
Dropout signal
–

Adverse events

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-07-07 (study day 2); relationship: not assessed

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-07-14 (study day 9); relationship: not assessed

mild assessed

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-07-22 (study day 17); relationship: N

severe serious assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-07-27 (study day 22); relationship: not assessed; serious criteria: hospitalization

severe assessed

Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-08-01 (study day 27); relationship: not assessed

Data queries

No data queries.